Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07222735 · ClinicalTrials.gov registry record · Phase 1

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

A Phase 1 study of Sarcoma and Ewing Sarcoma, sponsored by St. Jude Children's Research Hospital.

Recruiting
Registry status
Phase 1
Development phase
42
Enrollment target
1
Study location

NCT07222735 is a Phase 1 study of Sarcoma and Ewing Sarcoma that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 42 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07222735, a Phase 1 study of Sarcoma and Ewing Sarcoma, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.

RECRUITING
Registry status
Phase 1
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy. Primary objective: \- To evaluate the safety of B7-H3-CAR T cell therapy after priming with hypofractionated radiation therapy (HFRT) and lymphodepleting chemotherapy in patients ≤ 21 years of age with relapsed/refractory B7-H3+ sarcomas. Secondary objectives: * To describe the antitumor activity of B7-H3-CAR T cells in combination with HFRT * To determine if B7-H3-CAR T cells traffic to tumor sites after combination treatment with HFRT

Conditions Studied

Sarcoma Ewing Sarcoma Childhood Soft Tissue Sarcoma Childhood Rhabdomyosarcoma Childhood Osteosarcoma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • RADIATION Radiation Therapy
  • DRUG B7-H3-CAR T Cells

Study Locations (1)

Tennessee

  • St. Jude Children's Research Hospital - Memphis

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2026-01-21
Est. Completion 2031-11-05
Phase Phase 1

Sponsor

St. Jude Children's Research Hospital

410 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07222735

The ClinicalTrials.gov registry entry for NCT07222735 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.

NCT07222735 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT07222735 about?

NCT07222735 is a clinical study titled "Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas". RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy. Primary objective: \- To evaluate the safety of B7-H3-CAR T cell therapy after priming with hypofractionated radiation therapy (HFRT) and lymph...

What is the current status of trial NCT07222735?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2026-01-21. Estimated completion is 2031-11-05.

What conditions does trial NCT07222735 study?

This clinical trial studies the following conditions: Sarcoma, Ewing Sarcoma, Childhood Soft Tissue Sarcoma, Childhood Rhabdomyosarcoma, Childhood Osteosarcoma.

What interventions are being tested in trial NCT07222735?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Radiation Therapy (RADIATION), B7-H3-CAR T Cells (DRUG).

Who is sponsoring clinical trial NCT07222735?

This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07222735 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sarcoma

All registered trials for this condition

Ewing Sarcoma

All registered trials for this condition

Tennessee

All trials with a study site in Tennessee

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.